Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according to the HOVON 65/GMMG-HD4 study.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Jul 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

07 Jul 2011 New source identified and integrated (Netherlands Trial Register).
07 Jul 2011 Additional lead trial center identified as reported by Netherlands Trial Register.
07 Jul 2011 Planned end date changed from 7 Feb 2010 to 1 Apr 2010 as reported by Netherlands Trial Register.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight